Contact us
 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Rebamipide and Pantoprazole Combination in NSAIDs-Gastropathy Treatment
Author(s)
Maher Mbarki, Helen Sklyarova, Krystyna Aksentiychuk, Natalia Kharchenko and Eugene Sklyarov
Full-Text PDF
XML 698 Views
DOI:10.17265/2328-2150/2017.03.006
Affiliation(s)
ABSTRACT
The objective of this study was to investigate the pantoprazole and
rebamipide efficiency on NSAIDs (nonsteroidal
anti-inflammatory drugs)-gastropathy restoring
and healing in patients with coronary heart disease, stable angina, who have
been taking aspirin for a long time period. The study included three groups of
patients according to the treatment they have got: ASA (acetylsalicylic acid)
in the first group; ASA and pantoprazole in
the second; ASA, pantoprazole and
rebamipide in the third one. To obtain the results, endoscopic method and
proinflammatory cytokines LTB4 and protective prostaglandin E2 determination in
the blood were used. The research demonstrated no ulcer effects in the group of
patients who were treated by rebamipide, and significantly fewer gastroduodenal
erosions, in comparison to the group, where treatment contained ASA and
pantoprazole. The LTB4 (leukotriene B4) level decreased in
pantoprazole and rebamipide treatment groups, but the PGE2 (prostaglandin E2) level increased only
after rebamipide therapy. Therefore, rebamipide should be included to the
therapy for the better NSAIDs-gastropathy
treatment, in reason of its good reparative and gastroprotective properties.
KEYWORDS
NSAIDs, acetylsalicylic acid, pantoprazole, rebamipide, gastropathy, LTB4, PGE2.
Cite this paper
Mbarki, M., et al. 2017. “Rebamipide and Pantoprazole Combination in NSAIDs-Gastropathy Treatment.” Journal of Pharmacy and Pharmacology 5 (3): 153-157.
References